FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000104469> ?p ?o ?g. }

• W2000104469 endingPage "1383" @default.
• W2000104469 startingPage "1363" @default.
• W2000104469 abstract "Interferon (IFN) alfa is a clinically effective therapy used in a wide range of viral infections and cell-proliferative disorders. Combination therapy with IFN alfa-2b and ribavirin is the current standard of care for the treatment of chronic hepatitis C (CHC) infection. However, standard IFN alfa has the drawbacks of a short serum half-life and rapid clearance. To overcome this problem, 2 pegylated forms of IFN have been developed and tested clinically.This article reviews the development and properties of pegylated IFN alfa-2b and pegylated IFN alfa-2a, and presents safety and efficacy data from recent clinical trials.Relevant clinical studies were identified through a MEDLINE search from 1966 through the present using the key words hepatitis C and interferon. Studies of the pegylated IFNs in humans were then selected.Pegylated IFN alfa-2b is formed by covalent conjugation of a 12-kd mono-methoxy polyethylene glycol (PEG) molecule to IFN alfa-2b, and pegylated IFN alfa-2a by covalent conjugation of a 40-kd branched mono-methoxy PEG molecule to IFN alfa-2a. The 2 pegylated IFNs differ in the mixture of pegylation isomers resulting from their conjugation chemistry. Pegylated IFN alfa-2b has a prolonged serum half-life (40 hours) relative to standard IFN alfa-2b (7-9 hours). The greater polymer size of pegylated IFN alfa-2a acts to reduce glomerular filtration, markedly prolonging its serum half-life (72-96 hours) compared with standard IFN alfa-2a (6-9 hours). In clinical studies, once-weekly dosing of the pegylated IFNs was associated with a sustained virologic response in patients infected with hepatitis C virus (HCV). Once-weekly dosing with either of the pegylated IFNs was more effective than the respective thrice-weekly regimen of IFN alfa, with a comparable safety profile. The combination of once-weekly pegylated IFN and ribavirin effectively reduced HCV viral load and sustained viral suppression.Once-weekly dosing with either pegylated IFN alfa-2b or pegylated IFN alfa-2a has been shown to produce significantly higher rates of viral eradication than standard thrice-weekly IFN alfa therapy without compromising safety. With respect to the treatment of CHC, the greatest anti-HCV efficacy has been achieved with the combination of once-weekly pegylated IFN and ribavirin." @default.
• W2000104469 created "2016-06-24" @default.
• W2000104469 creator A5016708799 @default.
• W2000104469 creator A5023444728 @default.
• W2000104469 creator A5053117233 @default.
• W2000104469 creator A5064687707 @default.
• W2000104469 date "2002-09-01" @default.
• W2000104469 modified "2023-09-25" @default.
• W2000104469 title "Pegylated interferons for the treatment of chronic hepatitis C infection" @default.
• W2000104469 cites W141079205 @default.
• W2000104469 cites W1486067148 @default.
• W2000104469 cites W1490299254 @default.
• W2000104469 cites W1515293536 @default.
• W2000104469 cites W1556748674 @default.
• W2000104469 cites W1967556340 @default.
• W2000104469 cites W1976110218 @default.
• W2000104469 cites W1980221984 @default.
• W2000104469 cites W1982188484 @default.
• W2000104469 cites W1987119060 @default.
• W2000104469 cites W1990162272 @default.
• W2000104469 cites W2001627087 @default.
• W2000104469 cites W2002478100 @default.
• W2000104469 cites W2010506651 @default.
• W2000104469 cites W2011707824 @default.
• W2000104469 cites W2014616917 @default.
• W2000104469 cites W2015512183 @default.
• W2000104469 cites W2022098233 @default.
• W2000104469 cites W2029579670 @default.
• W2000104469 cites W2043519223 @default.
• W2000104469 cites W2045767384 @default.
• W2000104469 cites W2050347564 @default.
• W2000104469 cites W2052829077 @default.
• W2000104469 cites W2053876196 @default.
• W2000104469 cites W2055208820 @default.
• W2000104469 cites W2055589818 @default.
• W2000104469 cites W2059457521 @default.
• W2000104469 cites W2065225927 @default.
• W2000104469 cites W2065594131 @default.
• W2000104469 cites W2068431603 @default.
• W2000104469 cites W2069633422 @default.
• W2000104469 cites W2078993960 @default.
• W2000104469 cites W2079634214 @default.
• W2000104469 cites W2079771726 @default.
• W2000104469 cites W2081127519 @default.
• W2000104469 cites W2088748690 @default.
• W2000104469 cites W2100227035 @default.
• W2000104469 cites W2103565638 @default.
• W2000104469 cites W2105965047 @default.
• W2000104469 cites W2109397495 @default.
• W2000104469 cites W2117753850 @default.
• W2000104469 cites W2127685726 @default.
• W2000104469 cites W2142337801 @default.
• W2000104469 cites W2144653878 @default.
• W2000104469 cites W2153918414 @default.
• W2000104469 cites W2156574153 @default.
• W2000104469 cites W2165715544 @default.
• W2000104469 cites W2166971952 @default.
• W2000104469 cites W2316016553 @default.
• W2000104469 cites W2317554121 @default.
• W2000104469 cites W2328841790 @default.
• W2000104469 cites W2332630894 @default.
• W2000104469 cites W2334197314 @default.
• W2000104469 cites W2335845212 @default.
• W2000104469 cites W2336799715 @default.
• W2000104469 cites W2336924892 @default.
• W2000104469 cites W4312850899 @default.
• W2000104469 doi "https://doi.org/10.1016/s0149-2918(02)80042-x" @default.
• W2000104469 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12380630" @default.
• W2000104469 hasPublicationYear "2002" @default.
• W2000104469 type Work @default.
• W2000104469 sameAs 2000104469 @default.
• W2000104469 citedByCount "108" @default.
• W2000104469 countsByYear W20001044692012 @default.
• W2000104469 countsByYear W20001044692013 @default.
• W2000104469 countsByYear W20001044692014 @default.
• W2000104469 countsByYear W20001044692015 @default.
• W2000104469 countsByYear W20001044692016 @default.
• W2000104469 countsByYear W20001044692017 @default.
• W2000104469 countsByYear W20001044692018 @default.
• W2000104469 countsByYear W20001044692020 @default.
• W2000104469 countsByYear W20001044692021 @default.
• W2000104469 crossrefType "journal-article" @default.
• W2000104469 hasAuthorship W2000104469A5016708799 @default.
• W2000104469 hasAuthorship W2000104469A5023444728 @default.
• W2000104469 hasAuthorship W2000104469A5053117233 @default.
• W2000104469 hasAuthorship W2000104469A5064687707 @default.
• W2000104469 hasConcept C10138342 @default.
• W2000104469 hasConcept C126322002 @default.
• W2000104469 hasConcept C162324750 @default.
• W2000104469 hasConcept C185592680 @default.
• W2000104469 hasConcept C203014093 @default.
• W2000104469 hasConcept C2522874641 @default.
• W2000104469 hasConcept C2776178377 @default.
• W2000104469 hasConcept C2776408679 @default.
• W2000104469 hasConcept C2776455275 @default.
• W2000104469 hasConcept C2776461080 @default.
• W2000104469 hasConcept C2776964284 @default.
• W2000104469 hasConcept C2777288759 @default.

• next